Christopher Cannon, ADA 2020: Results of the Phase III VERTIS-CV Trial

It was a pleasure to speak to Christopher Cannon to discuss the much-anticipated results of the VERTIS-CV trial (ClinicalTrials.gov Identifier: NCT01986881) evaluating the efficacy and safety and cardiovascular outcomes of ertugliflozin in type 2 diabetes.

Questions

1. Could you tell us a little about the VERTIS-CV trial and its primary and secondary outcome data? (0:06)

2. What were the major safety findings, including the effects on diabetic ketoacidosis and acute kidney injury? (2:44)

3. How do these compare to data from the other SGLT2 cardiovascular outcome trials? (3:50)

4. Why do you think this study has not shown a statistically significant effect on reducing the incidence of CV disease death and heart failure hospitalisations? (4:42)

5. With an increasing number of SGLT inhibitors available, what factors should be considered in choosing between them? (6:18)

Speaker disclosure: Christopher Cannon has received research grants from Amgen, Boehringer-Ingelheim (BI), Bristol-Myers Squibb (BMS), Daiichi Sankyo, Janssen, Merck and Pfizer and consulting fees from Aegerion, Alnylam, Amarin, Amgen, Applied Therapeutics, Ascendia, BI, BMS, Corvidia, HLS Therapeutics, Innovent, Janssen, Kowa, Merck, Pfizer, Sanofi and Rhoshan.

Support: Interview commissioned and filming supported by Touch Medical Media.

Filmed in coverage of the ADA 2020 Virtual 80th Scientific Sessions.